Atorvastatin Recall Shows FDA Weakness in Control of Drugs Made Overseas

If you take cholesterol-lowering drugs known as statins, you may have noticed a flurry of news coverage since late October 2025 about an extensive recall of thousands of bottles of atorvastatin, the generic version of Lipitor, C. Michael White of the University of Connecticut wrote for The Conversation.

The atorvastatin recall is large, potentially affecting hundreds of thousands of patients. (Photo: Vastovers)

Both generic atorvastatin and brand-name Lipitor contain the same active ingredient, atorvastatin calcium, and are considered bioequivalent by the Food and Drug Administration (FDA).

This medication is the No. 1-selling drug in the U.S., with more than 115 million prescriptions written for over 29 million Americans.

The atorvastatin recall is large, potentially affecting hundreds of thousands of patients, but it is only the latest in a series of concerning manufacturing issues that have come to light since 2019.

Ascend Laboratories, based in New Jersey, originally issued the recall for about 142,000 bottles of its generic atorvastatin on Sept. 19.

Each bottle contained 90, 500, or 1,000 tablets — enough to fill prescriptions for three, 17, or 33 patients, respectively, for one month.

On Oct. 10, the FDA quantified the risk of using poor-quality tablets and gave the recall a Class II status, meaning the products could cause “temporary or medically reversible adverse health consequences.”

In this case, sample pills failed to dissolve properly when tested. Batches manufactured from November 2024 through September 2025 all had this defect.

When atorvastatin is swallowed, it must dissolve before the active ingredient can be absorbed by the body and transported to the liver, where it lowers concentrations of low-density lipoproteins — LDL, or “bad cholesterol.”

If the drug does not dissolve properly, the amount absorbed is substantially reduced.

Lowering LDL with atorvastatin has been shown to reduce cardiovascular events such as heart attacks and strokes by 22%.

When nearly 30,000 people in a 2021 study stopped taking their atorvastatin or another statin for six months, the risk of cardiovascular events, deaths, and emergency room visits increased by between 12% and 15%.